Unaudited Condensed Consolidated Interim Financial Statements
(Expressed in Canadian Dollars)

ENLIGHTA INC.

Three month periods ended September 30, 2022 and 2021

NOTICE TO READER

Under National Instrument 51-102, if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements have been prepared by management, and were not reviewed by the Company's independent auditor.

ENLIGHTA INC.

Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian dollars)
(Unaudited)

	September 30, 2022	June 30, 2022
Assets		
Current Assets		
Cash	$ 32,855	$ 41,654
Prepaid	11,337	3,704
Other receivables (note 6)	188	150
	44,380	45,508
Intangible asset (note 3)	1	1
Assignment rights (note 4)	1	1
	$ 44,382	$ 45,510
Liabilities and Shareholders' Equity		
Current Liabilities		
Trade and other payables	$ 565,238	$ 600,732
Due to related parties (note 6)	2,128,749	1,940,117
	2,693,987	2,540,849
Shareholders' equity:		
Share capital	28,827,754	28,827,754
Share-based payment reserve	928,034	928,034
Accumulated deficit	(32,405,393)	(32,251,127)
	(2,649,605)	2,495,339
Corporate information and going concern (note 1)		
	$ 44,382	$ 45,510

See accompanying notes to condensed consolidated interim financial statements.

Approved on behalf of the Board:

"Ben Wu" Director
Ben Wu

"Yun Zhu" Director
Yun Zhu

ENLIGHTA INC.

Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
(Expressed in Canadian dollars)
(Unaudited)

	Three months ended	
	September 30, 2022	September 30, 2021
Expenses:		
Amortization (note 3)	$ -	$ 78,801
General and administration (note 6 and 7)	134,170	164,697
Research and development	20,104	-
Loss before the undernoted items	(154,274)	(243,498)
Foreign exchange gain (loss)	8	892
Net loss and comprehensive loss for the period	$ (154,266)	$ (242,606)
Net loss per share basic and diluted (note 5(c))	$ (0.01)	$ (0.01)

See accompanying notes to condensed consolidated interim financial statements.

ENLIGHTA INC.

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Expressed in Canadian dollars)
(Unaudited)

Three month periods ended September 30, 2022 and 2021

	Number of shares	Share capital	Contributed surplus	Accumulated deficit	Total
Balance June 30, 2021	17,080,529	$ 28,827,754	$ 928,034	$ (28,624,414)	$ 1,131,374
Loss for the period	-	-	-	(242,606)	(242,606)
Balance September 30, 2021	17,080,529	$ 28,827,754	$ 928,034	$ (28,867,020)	$ 888,768
Balance June 30, 2022	17,080,529	$ 28,827,754	$ 928,034	$ (32,251,127)	$ (2,495,339)
Loss for the period	-	-	-	(154,266)	(154,266)
Balance September 30, 2022	17,080,529	$ 28,827,754	$ 928,034	$ (32,405,393)	$ 2,649,605

See accompanying notes to condensed consolidated interim financial statements.

ENLIGHTA INC.

Unaudited Condensed Consolidated Interim Statements of Cash Flows
(Expressed in Canadian dollars)

	Three months ended September 30, 2022	Three months ended September 30, 2021
Cash (used in) provided by:		
Operations:		
Net loss for the period	$ (154,266)	$ (242,606)
Items not involving cash		
Amortization	-	78,801
Changes in non-cash working capital:		
Prepaid	(7,633)	(27,660)
Receivables and other	(38)	(38)
Due from related parties	-	23,412
Accounts payable and accrued liabilities	(35,494)	48,591
Due to related party	188,632	88,293
Cash (used in) operating activities	(8,799)	(31,207)
Decrease in cash and cash equivalents	(8,799)	(31,207)
Cash and cash equivalents, beginning of period	41,654	59,844
Cash and cash equivalents, end of period	$ 32,855	$ 28,637

See accompanying notes to condensed consolidated interim financial statements.

1. Corporate information and going concern:

Enlighta Inc. ("Enlighta" or "Company") was originally incorporated on December 10, 2010 under the *Business Corporations Act* (British Columbia) as Avagenesis Corp. ("Avagenesis") and continued into Alberta, Canada on February 10, 2011. The Company is listed on the TSX Venture Exchange ("TSXV") under the symbol "NLTA". On December 31, 2016, Avagenesis completed an amalgamation arrangement with Avapecia Life Sciences Corp. ("Avapecia") and continued the business of both Avapecia and Avagenesis under the new name, Liberty Biopharma Inc.. Avagenesis was considered to have acquired the net assets of Avapecia and the consolidated financial statements of the amalgamated company are a continuation of the consolidated financial statements of Avagenesis. On September 25, 2018, the Company changed its name to HooXi Network Inc. The Company continued to the British Virgin Islands emigrating from British Columbia on April 3, 2019. On July 23, 2019, the Company changed its name to Enlighta Inc..

Enlighta is a diversified healthcare and medical digital, green and clean technology company active in global strategic partnerships and in licensing of technologies and assets for rapid growth and high value solutions.

In fiscal 2018 and 2019, the Company entered into agreements with Cloud Medical Group Inc. ("CMGI") and CTC Life Sciences Inc. ("HooXi"). Through these transactions, the Company will endeavour to expand its operations from developing and commercializing its legacy technologies to the acquisition and integration of joint ventures and intellectual property in health service delivery, biotechnology, green technology and allied services and digital assets and/or fintech. As at September 30, 2022, the Company had an accumulated deficit of $32,405,393. During the period ended September 30, 2022, the Company had no revenues and a net loss of $154,274. These conditions indicate a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to develop profitable operations in the future. The Company has generated operating losses since inception. Management is of the opinion that sufficient working capital will be obtained from external financing and future sales revenue to meet the Company's liabilities and commitments.

There can be no assurances that the Company will be successful in raising additional cash to finance operations or that the continued support of shareholders will be available. These consolidated financial statements have been prepared using the going concern assumption, which assumes that the Company will continue in operation for the foreseeable future. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Basis of preparation:

(a) Statement of compliance:

The unaudited condensed consolidated interim financial statements have been prepared using the same accounting policies and methods as those used in the audited consolidated financial statements for the year ended June 30, 2022 and in accordance with International Accounting Standard ("IAS") 34, "Interim Financial Reporting". These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended June 30, 2022.

These condensed consolidated interim financial statements were approved and authorized for issue by the Board of Directors on November 27, 2022.

(b) Basis of measurement:

These consolidated interim financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are recorded at fair value.

(c) Functional and presentation currency:

These consolidated interim financial statements are presented in Canadian dollars, which is the functional currency of the Company and its subsidiaries.

(d) Use of estimates and judgments:

The preparation of these consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates. Significant judgments made by management in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the consolidated interim financial statements include useful economic life of intangible assets, impairment assessment of intangible assets and the application of the going concern assumption.

(Expressed in Canadian dollars)

3. Intangible assets:

The Company owns a master global license for the use of technology related to an automated adipose tissue bioprocessing system for various specific clinical market indications. This master global license has no further royalty fees and expires on December 31, 2030.

During the year ended June 30, 2022, the Company anticipated difficulties in commercializing the licenses due to delay in clinical studies and uncertainty in obtaining funding and hence, has written down the intangible assets to a nominal value and recorded an impairment of $2,645,873.

As at September 30, 2022 and 2021, the Company had the following intangible assets:

September 30, 2022	Cost	Additions	Amortization	Accumulated amortization	Impairment	Net
License – adipose biotechnology	$ 4,571,267	$ -	$ 315,204	$ 1,925,393	$ (2,645,873)	$ 1
	$ 4,571,267	$ -	$ 315,204	$ 1,925,393	$ (2,645,873)	$ 1

September 30, 2021	Cost	Additions	Amortization	Accumulated amortization	Impairment	Net
License – adipose biotechnology	$ 4,571,267	$ -	$ 315,204	$ 1,688,990	-	$ 2,882,277
	$ 4,571,267	$ -	$ 315,204	$ 1,688,990	-	$ 2,882,277

At September 30, 2022, the Company did not have any indefinite life intangible assets.

4. Financial instruments – assignment rights:

On December 31, 2017, Enlighta completed an acquisition and share exchange transaction (“CMGI Transaction”) with CMGI shareholders. CMGI was a privately held company incorporated under the BC Companies Act in 2014 that held a series of agreements (“the Assignment Rights”) that were acquired by CMGI in January of 2017 and which entitle CMGI to cash flows earned from various medical-related joint ventures and license arrangements entered into by private companies operating in Mainland China. Certain shareholders in CMGI before the CMGI Transaction were instrumental in negotiating and will continue to manage the Chinese joint ventures and licensing arrangements on a go-forward basis. Management considered these business relationships to be a key component of the benefits acquired in the CMGI Transaction.

The Assignment Rights acquired in the CMGI Transaction pertain to business arrangements that are in their early stages. The Company has determined that the fair value of these Assignment Rights is nominal and assigned a value of $1 upon acquisition. In future periods, the Assignment Rights continue to be recorded at management’s estimate of their fair value determined by reference to the expected future cash flows to be generated by the underlying medical related joint ventures and license arrangements. Any future increase in the fair value of the Assignment Rights would result in a gain recorded through the Consolidated Statements of Comprehensive Loss.

(Expressed in Canadian dollars)

5. Share capital:

(a) Authorized share capital:

Unlimited voting, participating common shares, with no par value.

Unlimited preferred shares, issuable in series.

The preferred shares may be issued in one or more series and the directors are authorized to fix the number of shares in each series and to determine the designation, rights, privileges, restrictions, and conditions attached to the shares of each series.

(b) Warrants:

The following summarizes information about the Company's share purchase warrants outstanding:

Outstanding as at September 30, 2022	Fair value	Number of Warrants	Weighted average exercise price	Weighted average life
Warrants	$ -	-	$ -	-

Outstanding as at September 30, 2021	Fair value	Number of Warrants	Weighted average exercise price	Weighted average life
Warrants	$ 212,968	213,393	$ 7.50	0.74 years

(c) Earnings per share computation:

The following table sets forth the computation of loss per common share:

	Three months ended September 30, 2022	Three months ended September 30, 2021
Loss for the period	$ (154,266)	$ (242,606)
Weighted average number of common shares outstanding	17,080,529	17,080,529
Net loss per share basic and diluted	$ (0.01)	$ (0.01)

(Expressed in Canadian dollars)

5. Share capital (continued):

(d) Stock options:

On December 5, 2018, the Company granted to certain Directors, Management and Consultants, non-transferable options ("Management Options") to purchase 1,710,000 common shares. The Management Options are exercisable at a price of $0.72 per share for a period of 60 months from the date of issuance and vested immediately. The Company has accounted for the options using the fair value method and, accordingly, has recorded the amount of $596,189 ($0.3486 per option) to Stock option expense with a corresponding addition to contributed surplus. The fair value of the Management Options on the amalgamation date was estimated using the Black-Scholes options pricing model based on the following assumptions: Dividend yield (Nil), expected volatility (50%), forfeiture rate (0%), risk free interest rate (2.01%) and expected life (2.5 years).

As at September 30, 2022 there were 900,000 options outstanding.

6. Related party transactions:

Related parties include shareholders with a significant ownership interest in the Company, its subsidiaries, affiliates of shareholders with a significant ownership interest in the Company, and the Company's key management personnel. The related party transactions have been valued in these financial statements at fair value, which is the amount of consideration established and agreed to by the related parties.

(a) Balances with related parties:

	September 30, 2022	September 30, 2021
Due from related parties	$ -	$ 211,406
Due to related parties	2,128,749	1,865,791

(b) Transactions during the period with related parties:

	Three months ended	
	September 30, 2022	September 30, 2021
Office (included in general and administration)	$ -	$ 9,000

(Expressed in Canadian dollars)

7. General and administrative expenses

The amount in general and administration is comprised of the following:

	Three months ended September 30, 2022	September 30, 2021
Salaries and benefits	$ 59,567	$ 76,063
Professional fees	64,999	68,018
Office and other	9,604	20,616
Total	$ 134,170	$ 164,697